CRL · Charles River Laboratories Inte
$345.37
+1.68% last session
End-of-day data · close of 2026-10-23
Market cap
$16B
Enterprise value
$19B
Trailing P/E
—
Forward P/E
27.1
Dividend yield
0.0%
Beta
1.40
Avg volume
1M
Employees
18K
Daily Change %
1.68%
5 Days Change
13.16%
10 Days Change
13.59%
30 Days Change
22.48%
60 Days Change
13.76%
Month to Day Change
18.42%
Year to Day Change
70.27%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — CRL
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-13
Latest call per bank · past 12 months
Morgan Stanley
Overweight$340
-1.6% vs priceJefferies
Buy$340
-1.6% vs priceDeutsche Bank
Buy$320
-7.3% vs priceRBC Capital
Outperform$322
-6.8% vs priceBarclays
Overweight$330
-4.5% vs priceJP Morgan
Overweight$310
-10.2% vs priceUBS
Neutral$175
-49.3% vs priceCitigroup
Buy$265
-23.3% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | Morgan Stanley | Maintains | Overweight | $300 → $340 |
| 2026-09-28 | Jefferies | Maintains | Buy | $305 → $340 |
| 2026-09-25 | Deutsche Bank | Maintains | Buy | $300 → $320 |
| 2026-09-25 | TD Cowen | Maintains | Buy | $300 → $325 |
| 2026-09-25 | Evercore ISI Group | Maintains | Outperform | $320 → $330 |
| 2026-09-25 | RBC Capital | Maintains | Outperform | $282 → $322 |
| 2026-09-25 | Barclays | Maintains | Overweight | $300 → $330 |
| 2026-09-25 | Mizuho | Maintains | Neutral | $264 → $295 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- bearish: RSI (14): RSI is 73 — overbought territory; the recent run-up may be due for a pause.
- bullish: Price vs 50-day MA: Trading 17.5% above the 50-day MA ($293.94).
- bullish: Price vs 200-day MA: Trading 58.4% above the 200-day MA ($218.11).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+4.24) — short-term momentum is improving.
- bullish: 52-week range: Price is within 5% of the 52-week high ($345.37).
CRL Price Chart
Loading chart for CRL…
Fundamentals
About Charles River Laboratories Inte
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
More in Diagnostics & Research
TMO
Thermo Fisher Scientific Inc
$249B 17.1% YTD
DHR
Danaher Corporation
$162B 1.0% YTD
NTRA
Natera, Inc.
$58B 75.2% YTD
A
Agilent Technologies, Inc.
$49B 28.7% YTD
IQV
IQVIA Holdings, Inc.
$46B 23.5% YTD
WAT
Waters Corporation
$45B 20.0% YTD
IDXX
IDEXX Laboratories, Inc.
$44B -16.2% YTD
ILMN
Illumina, Inc.
$41B 105.4% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.